NanoViricides Reports Breakthrough Anti-Measles Results for Broad-Spectrum Antiviral NV-387

NanoViricides, Inc. (NYSE American: NNVC) has revealed significant progress in developing a potential treatment for Measles, a viral disease that currently lacks approved therapeutic options. During a video interview available at https://youtu.be/m_3Yk4_832E, CEO Dr. Anil Diwan discussed how the company's lead candidate NV-387 demonstrated strong anti-Measles activity in both cell culture and humanized animal models. The experimental drug extended survival by 130% and protected lung tissue during severe infection stages, representing a potential breakthrough in Measles treatment.

The significance of these findings cannot be overstated given the current global Measles landscape. With no approved treatments available, healthcare providers have limited options beyond supportive care for patients suffering from this highly contagious viral disease. The emergence of NV-387 as a potential therapeutic option comes at a critical time when Measles outbreaks have been increasing worldwide, partly due to vaccination gaps and pandemic-related disruptions to routine immunization programs.

NV-387 has already completed Phase I human trials with no reportable adverse events, establishing an important safety profile for the drug candidate. The company is now advancing the drug to Phase II trials for MPox, another viral indication, while positioning itself to support FDA emergency use applications and investigator-initiated Investigational New Drug applications for urgent Measles cases. This dual-track approach could accelerate the drug's availability for patients in critical need.

The broader implications of NV-387's success extend beyond Measles treatment alone. As a broad-spectrum antiviral, NV-387 represents NanoViricides' platform technology for treating multiple viral infections. The company plans to develop the drug as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. This multi-indication strategy could revolutionize antiviral therapy by providing a single therapeutic option for multiple viral threats.

NanoViricides' business model relies on licensing technology from TheraCour Pharma Inc. for specific antiviral applications, as detailed in their corporate information available at https://www.nanoviricides.com. The company holds exclusive worldwide perpetual licenses for several viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes viruses, Influenza, Dengue, Ebola/Marburg viruses, and certain Coronaviruses. This extensive portfolio positions the company as a significant player in the antiviral pharmaceutical space.

The potential impact of successful Measles treatment development extends to public health systems globally. Measles remains a leading cause of vaccine-preventable death in children worldwide, particularly in developing countries. An effective therapeutic could complement vaccination efforts by providing treatment options for breakthrough cases and protecting vulnerable populations who cannot receive vaccines due to medical contraindications. The availability of NV-387 could also help manage outbreaks in healthcare settings and reduce transmission rates in communities with low vaccination coverage.

For the pharmaceutical industry, NanoViricides' approach represents an innovative strategy in antiviral development. The company's nanoviricide technology platform creates special purpose nanomaterials designed to combat viral infections through a novel mechanism of action. If successful, this technology could establish new standards for antiviral drug development and potentially address the growing challenge of antiviral resistance. The company's progress with NV-387 against Measles demonstrates the platform's versatility and broad-spectrum potential, offering hope for addressing multiple viral threats with a single technological approach.